Table 3.
Associations of tumor characteristics with Parkinson’s disease gene mRNA relative expression in NSCLC
| Tumor characteristics | n (%) | PARK1/4 (SCNA) | PARK2(Parkin) | PARK5(UCHL-1) | PARK6(PINK1) | PARK7(DJ-1) | PARK8(LRRK2) | PARK9(ATP13A2) | PARK15(FBXO7) | GBA | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Means ± SD | P | Means ± SD | P | Means ± SD | P | Means ± SD | P | Means ± SD | P | Means ± SD | P | Means ± SD | P | Means ± SD | P | Means ± SD | P | |||||||||||
| Overall | 114 (100.00%) | 1.475 ± 1.088 | 3.177 ± 3.646 | 18.375 ± 15.551 | 5.465 ± 4.949 | 2.773 ± 2.336 | 2.272 ± 2.350 | 8.356 ± 7.402 | 1.956 ± 1.783 | 5.936 ± 4.328 | ||||||||||||||||||
| Gender | ||||||||||||||||||||||||||||
| Male | 72 (63.16%) | 1.499 ± 1.099 | 3.095 ± 3.974 | 18.349 ± 16.095 | 5.566 ± 4.993 | 2.638 ± 2.079 | 2.336 ± 2.357 | 8.329 ± 7.751 | 2.207 ± 1.938 | 6.472 ± 4.709 | ||||||||||||||||||
| Female | 42 (39.84%) | 1.433 ± 1.079 | .755a1 | 3.317 ± 3.044 | .756a1 | 18.419 ± 14.760 | .982a1 | 5.291 ± 4.927 | .776a1 | 3.005 ± 2.733 | .422a1 | 2.161 ± 2.362 | .703a1 | 8.401 ± 6.852 | .960a1 | 1.524 ± 1.398 | .500a2 | 5.016 ± 3.443 | .147a2 | |||||||||
| Histology | ||||||||||||||||||||||||||||
| Adenocarcinoma | 64 (56.14%) | 1.584 ± 1.080 | 4.900 ± 4.200 | 18.383 ± 14.360 | 5.422 ± 5.595 | 3.085 ± 2.710 | 2.346 ± 2.241 | 8.904 ± 7.890 | 2.125 ± 1.945 | 6.857 ± 4.274 | ||||||||||||||||||
| Squamous cell carcinoma | 50 (44.86%) | 1.367 ± 1.116 | .303b1 | 1.202 ± 1.043 | .000b2 | 18.784 ± 17.247 | .894b1 | 5.436 ± 3.857 | .988b1 | 2.410 ± 1.823 | .005b1 | 1.901 ± 1.871 | .274b1 | 7.557 ± 6.534 | .337b1 | 1.775 ± 1.617 | .311b1 | 5.642 ± 3.733 | .282b1 | |||||||||
| Tumor stage | ||||||||||||||||||||||||||||
| Stage I | 36 (31.58%) | 1.723 ± 1.371 | .280c1 | I–II | 5.403 ± 5.442 | .040c2 | I–II | 22.808 ± 18.141 | .410c2 | I–II | 7.404 ± 6.642 | .995c1 | I–II | 4.074 ± 3.377 | .003c2 | I–II | 1.631 ± 1.391 | .040c2 | I–II | 9.608 ± 9.410 | .427c2 | I–II | 3.240 ± 2.546 | .070c2 | I–II | 6.440 ± 5.055 | .450c1 | I–II |
| Stage II | 53 (46.49%) | 1.457 ± 0.936 | .176c1 | II–III | 2.217 ± 1.783 | .598c1 | II–III | 14.625 ± 11.716 | 3.27c2 | II–III | 5.362 ± 4.101 | .010c2 | II–III | 1.894 ± 0.743 | .105c2 | II–III | 3.306 ± 2.880 | .000c2 | II–III | 6.626 ± 5.645 | .180c1 | II–III | 1.567 ± 0.818 | .000c2 | II–III | 5.700 ± 4.131 | .098c1 | II–III |
| Stage III | 25 (21.93%) | 1.155 ± 0.854 | .720c1 | I–III | 2.001 ± 1.278 | .130c1 | I–III | 19.939 ± 17.271 | .538c2 | I–III | 2.891 ± 1.406 | .003c2 | I–III | 2.765 ± 1.904 | .215c2 | I–III | 1.002 ± 1.904 | .100c2 | I–III | 10.198 ± 6.880 | .790c1 | I–III | 0.930 ± 0.398 | .000c2 | I–III | 5.714 ± 3.663 | .542c1 | I–III |
I–II means the compare between stages I and II, II–III means the compare between stages II and III, I–III means the compare between stages I and III
a: Test for equality of medians between different gene relative expression and different sex: a1two-sided Student’s t-test; a2two-sided Wilcoxon rank sum test
b: Test for equality of medians between different gene relative expression and different tumor histology: b1two-sided Student’s t-test; b2two-sided Wilcoxon rank sum test
c: Test for equality of medians between different gene relative expression and different tumor stage: c1two-sided Student’s t-test; c2two-sided Wilcoxon rank sum test